The T-Force study is an open-label, multi-dose, two-week study of 36 subjects with Tourette syndrome. Children and adolescents will receive once-daily dosing of NBI-98854 during a two-week treatment
Prima will pay consideration of up to approximately US$28 M through a combination of cash, shares and warrants subject to the achievement of certain performance milestones. The transaction
Combined net sales of the Products during the twelve month period ending August 31, 2014 were approximately CDN$10.8 million. Fiorinal and Fiorinal C are indicated for the relief
The expansion significantly increases plasma processing and albumin production capacity in the Kankakee, Ill. facility. The new facility will use the same state-of-the-art technology as CSL Behring’s long-standing
AG’s IP is comprised of T Cells Receptor ("TCR") clonality analysis technology and T Central Memory Cell ("Tcm") and Dendritic Cell ("DC") preparation methodologies. The TCR clonality analysis
The issued patent # 8,846,635 is titled, "Method for inducing hepatocyte proliferation and uses thereof." Can-Fite has recently been granted a patent for this technology in Japan and
The patent, which extends through 2032, provides composition of matter protection for KP511, KemPharm’s prodrug of hydromorphone, and adds to the intellectual property estate governing the company’s pain
This project is part of CDC’s surveillance effort, with the potential to continue up to 5 years. KAI is a full-service Contract Research Organization providing support to both
Abilify Maintena is an atypical antipsychotic indicated for the treatment of schizophrenia; efficacy was demonstrated in a placebo-controlled, randomized-withdrawal maintenance trial in patients with schizophrenia and additional support
"With ImmunoClin’s track record in assisting biotech, pharma and food companies as well as public institutions in pharmaceutical and nutraceutical development projects, we are excited to initiate this
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.